Impact of type 2 diabetes mellitus on acute levodopa responsiveness in Parkinson's disease: A Multicenter retrospective study
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a common comorbidity in Parkinson's disease (PD) and may influence the progression and dopaminergic function, suggesting a potential impact on levodopa responsiveness.
Objective: To examine the impact of T2DM status on levodopa responsiveness in an acute levodopa challenge in PD.
Methods: We retrospectively analyzed the total and subdomain motor responses in the acute levodopa challenge in 136 PD patients with normal glycemic status, prediabetes, or T2DM across three German centers.
Results: Levodopa responsiveness did not differ significantly among the three glycemic groups. The only between-group difference was more severe rest tremor in T2DM patients in the OFF state, which was no longer present in the ON state due to greater levodopa-induced improvement.
Conclusion: An acute levodopa challenge remained similarly effective across glycemic groups in PD, suggesting that T2DM does not substantially modify acute dopaminergic treatment response. Future studies should also evaluate chronic response to levodopa across different glycemic statuses.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.